Evidence map›Paper›PMID 26169871›Full record

Trial reportEuropean journal of nutrition2016

Effects of wheat bran extract rich in arabinoxylan oligosaccharides and resistant starch on overnight glucose tolerance and markers of gut fermentation in healthy young adults.

Elin V Johansson Boll, Linda M N K Ekström, Christophe M Courtin, Jan A Delcour, Anne C Nilsson, Inger M E Björck, Elin M Östman

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05689684 (Arabinoxylan-oligosaccharides), which is not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05689684 nacompletednot on this mapstarted 2022, after this paper: background citation

Arabinoxylan-oligosaccharides (AXOS) As a Medical Food for Adjuvant Approach in the Management of Type-2 Diabetes

TypeinterventionalSponsorLund UniversityRan2022 to 2024Enrolled66ConditionsDiabetes Type 2ArmsAG+XOS+AXOS, Placebo Maltodextrin
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Elin V Johansson BollFood for Health Science Centre, Lund University, Lund, Sweden.
Linda M N K EkströmFood for Health Science Centre, Lund University, Lund, Sweden.
Christophe M CourtinLaboratory of Food Chemistry and Biochemistry and Leuven Food Science and Nutrition Research Centre (LFORCE), Department of Microbial and Molecular Systems (M2S), KU Leuven, Leuven, Belgium.
Jan A DelcourLaboratory of Food Chemistry and Biochemistry and Leuven Food Science and Nutrition Research Centre (LFORCE), Department of Microbial and Molecular Systems (M2S), KU Leuven, Leuven, Belgium.
Anne C NilssonFood for Health Science Centre, Lund University, Lund, Sweden.
Inger M E BjörckFood for Health Science Centre, Lund University, Lund, Sweden.
Elin M ÖstmanFood for Health Science Centre, Lund University, Lund, Sweden. Elin.Ostman@food-health-science.lu.se.ORCID http://orcid.org/0000-0003-0831-6176
Lund University · SEKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSpecific combinations of dietary fiber (DF) have been observed to result in improved glucose tolerance at a subsequent standardized breakfast. Arabinoxylan oligosaccharides (AXOS) are considered as DF with prebiotic potential, but so far no studies have investigated their metabolic effects in humans. This randomized cross-over study evaluated the overnight impact of breads containing AXOS-rich wheat bran extract and resistant starch (RS, Hi-Maize), separately or combined, on glucose tolerance, related metabolic parameters and markers of gut fermentation in healthy subjects.

methodsEvening reference and test products were: (1) reference white wheat flour bread (WWB), WWB supplemented with (2) AXOS and RS (WWB + AXOS + RS), (3) an increased content of either AXOS (WWB + hiAXOS) or (4) RS (WWB + hiRS). At the subsequent standardized breakfast, blood was sampled for 3 h to monitor glucose, insulin, nonesterified fatty acids, glucagon-like peptide (GLP)-1 and GLP-2. Breath hydrogen (H2) and short chain fatty acids (SCFA) were measured as markers of gut fermentation, and subjective appetite was rated using visual analog scales.

resultsDose-dependent decreases in glucose responses were observed with increased AXOS over the duration of 3 h. Insulin sensitivity index was improved in the morning after the WWB + hiAXOS evening meal. An increase in breath H2 concentration and circulating SCFA was observed in the morning after both evening meals containing AXOS.

conclusionThe present study indicates that AXOS have the potential of improving glucose tolerance in an overnight perspective and suggested mechanisms are improved insulin sensitivity and increased gut fermentation.

Indexed as

Food, FortifiedAdultAppetiteBiomarkersBlood GlucoseBody Mass IndexBreadBreakfastBreath TestsCross-Over StudiesDietary FiberFatty Acids, NonesterifiedFatty Acids, VolatileFemaleFermentationFlourarabinoxylanBiomarkersBlood GlucoseDietary FiberFatty Acids, NonesterifiedFatty Acids, VolatileGlucagon-Like Peptide 1Glucagon-Like Peptide 2InsulinOligosaccharidesPrebioticsStarchXylansArabinoxylan oligosaccharidesGlucose toleranceGut fermentationHealthy subjectsOvernightResistant starch

Identifiers

PMID26169871
OpenAlexW1784286813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.